Professional Overview
Larry Saltzman is an experienced healthcare executive with a strong background in medical research and clinical practice. As the Executive Research Director at the Leukemia and Lymphoma Society, he leverages his expertise in family medicine and executive leadership to drive innovative research initiatives and improve patient outcomes.
Experience Summary
Current Role
Since 2014, Larry has served as the Executive Research Director at the Leukemia and Lymphoma Society, where he oversees the organization's research portfolio and collaborates with a team of medical experts to identify and support promising lines of inquiry. In this role, he has been instrumental in securing funding for cutting-edge research projects and fostering partnerships with leading academic institutions and healthcare providers.
Career Progression
Prior to his current position, Larry spent over three decades as a practicing physician in a family medicine practice, providing comprehensive primary care services to patients. Additionally, he served as the CEO of Insurance Benefit Spot Check, Inc. from 1990 to 2005, where he successfully led the company's growth and strategic initiatives.
Academic Background
Larry holds a Doctor of Medicine (MD) degree from the Chicago Medical School at Rosalind Franklin University of Medicine and Science, and he completed his Family Medicine Residency Program at the University of California, Davis - School of Medicine. He also earned a Bachelor of Science (B.S.) in Biology, General from Washington University in St. Louis.
Areas of Expertise
- Medical research and clinical trials
- Healthcare policy and regulatory compliance
- Executive leadership and strategic planning
- Family medicine and primary care delivery
- Healthcare technology and data analysis
Professional Impact
During his tenure at the Leukemia and Lymphoma Society, Larry has been instrumental in securing over $15 million in research grants, enabling the organization to fund cutting-edge studies on new treatment approaches and early detection methods. He has also spearheaded the development of a groundbreaking patient education program, which has been widely recognized for its impact on improving health outcomes and enhancing the patient experience.
Conclusion
With his extensive experience in healthcare, medical research, and executive leadership, Larry Saltzman is a valuable asset to the Leukemia and Lymphoma Society. His commitment to advancing the understanding and treatment of blood cancers, combined with his proven track record of innovation and collaboration, positions him as a highly respected leader in the industry.
